StockNews.com Initiates Coverage on Navidea Biopharmaceuticals (NYSE:NAVB)

Equities research analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report issued on Tuesday. The firm set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Shares of NAVB stock opened at $0.00 on Tuesday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.15. The firm has a market cap of $100,080.00, a P/E ratio of -0.02 and a beta of 1.47. The business’s 50 day moving average price is $0.03 and its 200-day moving average price is $0.04.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.